Abbott links up with Advanced Life Science Institute (ALSI) on ProGRP (Pro-gastrin-releasing peptide) lung cancer test agreement:
This article was originally published in Clinica
Executive Summary
Abbott Diagnostics has obtained worldwide rights to commercialise products using Advanced Life Science Institute's (ALSI) Pro-gastrin-releasing peptide (ProGRP) biomarker, which could be used to earlier diagnose small cell lung cancer. Abbott plans to use ProGRP to widen the menu on one of its analysers, most likely a menu from its Architect, or AxSYM range, said the firm. ProGRP has shown promise in preliminary studies as a test for lung cancer. "Through automation, this marker could be further refined for clinical use," commented William Brown, Abbott's vice-president of diagnostic assays and systems development. ALSI, based in Saitama, Japan, hopes that the agreement will enable its tumour maker technology to "reach a wider audience".
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.